A previous study identified EGFR and KRAS mutations in 21% and 25% of cases15 reported by the Lung Cancer Mutation Consortium, respectively, and 14% and 33% of cases in The Cancer Genome Atlas, respectively.8 This evidence concerns the gene KRAS and lung carcinoma.